Cwm LLC Buys 598 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Cwm LLC increased its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 37.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,174 shares of the company’s stock after buying an additional 598 shares during the period. Cwm LLC’s holdings in Dr. Reddy’s Laboratories were worth $151,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of RDY. Allspring Global Investments Holdings LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 8.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 115,499 shares of the company’s stock worth $8,036,000 after acquiring an additional 9,414 shares during the period. Sequoia Financial Advisors LLC grew its holdings in Dr. Reddy’s Laboratories by 3.6% in the 4th quarter. Sequoia Financial Advisors LLC now owns 14,294 shares of the company’s stock valued at $995,000 after buying an additional 501 shares in the last quarter. Wellington Management Group LLP grew its holdings in Dr. Reddy’s Laboratories by 40.7% in the 3rd quarter. Wellington Management Group LLP now owns 141,154 shares of the company’s stock valued at $9,439,000 after buying an additional 40,825 shares in the last quarter. Nordea Investment Management AB increased its position in Dr. Reddy’s Laboratories by 5.3% during the 3rd quarter. Nordea Investment Management AB now owns 23,855 shares of the company’s stock worth $1,601,000 after buying an additional 1,196 shares during the period. Finally, Schroder Investment Management Group boosted its position in shares of Dr. Reddy’s Laboratories by 62.4% in the third quarter. Schroder Investment Management Group now owns 150,165 shares of the company’s stock valued at $10,042,000 after acquiring an additional 57,681 shares during the period. Institutional investors and hedge funds own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 0.6 %

Shares of Dr. Reddy’s Laboratories stock opened at $75.21 on Monday. The firm’s 50-day moving average price is $73.97 and its two-hundred day moving average price is $70.75. The company has a market capitalization of $12.55 billion, a price-to-earnings ratio of 19.84, a PEG ratio of 1.88 and a beta of 0.57. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 12-month low of $53.12 and a 12-month high of $77.72.

Wall Street Analyst Weigh In

A number of research firms recently commented on RDY. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Jefferies Financial Group cut Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. Finally, Barclays raised their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, January 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $80.00.

About Dr. Reddy’s Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.